Compared to the control group, the p-AMPK expression was significantly decreased in the NAFLD group, and KTZG treatment increased the expression significantly in the 3 g/kg group (P < 0.05); p-mTOR expression was significantly increased in the NAFLD group, and KTZG treatment increased the expression significantly in the 1.5 g/kg and 3 g/kg groups (P < 0.05 and P < 0.01, respectively) (Figure 5(b)). Here, MTOR is linked to metabolic dysfunction-associated steatotic liver disease.